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PEPTIDE NUCLEIC ACIDS HAVING 
ENHANCED BINDING AFFINITY, 
SEQUENCE SPECIFICITY AND SOLUBILITY 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is a continuation-in-part of US. appli 
cations Ser. Nos: 08/685,484, now US. Pat. No. 5,719,262; 
08/686,116, now US. Pat. No. 5,714,331; 08/686,114 now 
US. Pat. No. 6,414,112 and 08/686,113, now US. Pat. No. 
5,766,855; each of Which Were ?led Jul. 24, 1996, each of 
Which is a continuation-in-part of US. application Ser. No: 
08/108,591, ?led Nov. 22, 1993, now US. Pat. No. 6,395, 
474; Which is a continuation-in-part of Danish Patent Appli 
cation No. 986/91, ?led May 24, 1991, Danish Patent 
Application No. 987/91, ?led May 24, 1991, and Danish 
Patent Application No. 510/92, ?led Apr. 15, 1992. This 
application also claims bene?t of, and is a continuation-in 
part of US. provisional application No. 60/051,002, ?led 
May 29, 1997. The entire disclosure of each of the above 
mentioned applications is incorporated herein by reference. 
FIELD OF THE INVENTION 
The present invention is directed to methods for enhanc 
ing sequence speci?city, binding affinity and solubility of 
peptide nucleic acids (PNAs) in Which naturally-occurring 
nucleobases or non-naturally-occurring nucleobases are 
covalently bound to a polyamide backbone. The PNAs of the 
present invention comprise at least one C1—C8 alkylamine 
side chain resulting in enhanced solubility, binding af?nity 
to nucleic acids and sequence speci?city as Well as other 
bene?cial qualities. In certain aspects, the present invention 
is directed to histidine-containing peptide nucleic acids and 
to synthetic intermediates employed in preparing such com 
pounds. 
BACKGROUND OF THE INVENTION 
The function of a gene starts by transcription of its 
information to a messenger RNA (mRNA). By interacting 
With the ribosomal complex, mRNA directs synthesis of the 
protein. This protein synthesis process is knoWn as transla 
tion. Translation requires the presence of various cofactors, 
building blocks, amino acids and transfer RNAs (tRNAs), 
all of Which are present in normal cells. 
Most conventional drugs exert their effect by interacting 
With and modulating one or more targeted endogenous 
proteins, e.g., enZymes. Typically, hoWever, such drugs are 
not speci?c for targeted proteins but interact With other 
proteins as Well. Thus, use of a relatively large dose of drug 
is necessary to effectively modulate the action of a particular 
protein. If the modulation of a protein activity could be 
achieved by interaction With or inactivation of mRNA, a 
dramatic reduction in the amount of drug necessary, and the 
side-effects of the drug, could be achieved. Further reduc 
tions in the amount of drug necessary and the side-effects 
could be obtained if such interaction is site-speci?c. Since a 
functioning gene continually produces mRNA, it Would be 
even more advantageous if gene transcription could be 
arrested in its entirety. Oligonucleotides and their analogs 
have been developed and used as diagnostics, therapeutics 
and research reagents. One example of a modi?cation to 
oligonucleotides is labeling With non-isotopic labels, e.g., 
?uorescein, biotin, digoxigenin, alkaline phosphatase, or 
other reporter molecules. Other modi?cations have been 
made to the ribose phosphate backbone to increase the 
resistance to nucleases. These modi?cations include use of 
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linkages such as methyl phosphonates, phosphorothioates 
and phosphorodithioates, and 2‘-O-methyl ribose sugar moi 
eties. Other oligonucleotide modi?cations include those 
made to modulate uptake and cellular distribution. Phos 
phorothioate oligonucleotides are presently being used as 
antisense agents in human clinical trials for the treatment of 
various disease states. Although some improvements in 
diagnostic and therapeutic uses have been realiZed With 
these oligonucleotide modi?cations, there exists an ongoing 
demand for improved oligonucleotide analogs. 
In the art, there are several knoWn nucleic acid analogs 
having nucleobases bound to backbones other than the 
naturally-occurring ribonucleic acids or deoxyribonucleic 
acids. These nucleic acid analogs have the ability to bind to 
nucleic acids With complementary nucleobase sequences. 
Among these, the peptide nucleic acids (PNAs), as 
described, for example, in WO 92/20702, have been shoWn 
to be useful as therapeutic and diagnostic reagents. This may 
be due to their generally higher affinity for complementary 
nucleobase sequence than the corresponding Wild-type 
nucleic acids. 
PNAs are compounds that are analogous to 
oligonucleotides, but differ in composition. In PNAs, the 
deoxyribose backbone of oligonucleotide is replaced by a 
peptide backbone. Each subunit of the peptide backbone is 
attached to a naturally-occurring or non-naturally-occurring 
nucleobase. One such peptide backbone is constructed of 
repeating units of N-(2-aminoethyl)glycine linked through 
amide bonds. 
PNAs bind to both DNA and RNA and form PNA/DNA 
or PNA/RNA duplexes. The resulting PNA/DNA or PNA/ 
RNA duplexes are bound tighter than corresponding DNA/ 
DNA or DNA/RNA duplexes as evidenced by their higher 
melting temperatures (Tm). This high thermal stability of 
PNA/DNA(RNA) duplexes has been attributed to the neu 
trality of the PNA backbone, Which results elimination of 
charge repulsion that is present in DNA/DNA or RNA/RNA 
duplexes. Another advantage of PNA/DNA(RNA) duplexes 
is that Tm is practically independent of salt concentration. 
DNA/DNA duplexes, on the other hand, are highly depen 
dent on the ionic strength. 
Homopyrimidine PNAs have been shoWn to bind comple 
mentary DNA or RNA forming (PNA)2/DNA(RNA) tri 
plexes of high thermal stability (Egholm et al., Science, 
1991, 254, 1497; Egholm et al., J. Am. Chem. Soc., 1992, 
114, 1895; Egholm et al., J. Am. Chem. Soc., 1992, 114, 
9677). 
In addition to increased affinity, PNAs have increased 
speci?city for DNA binding. Thus, a PNA/DNA duplex 
mismatch shoW 8 to 20° C. drop in the Tm relative to the 
DNA/DNA duplex. This decrease in Tm is not observed With 
the corresponding DNA/DNA duplex mismatch (Egholm et 
al., Nature 1993, 365, 566). 
The binding of a PNA strand to a DNA or RNA strand can 
occur in one of tWo orientations. The orientation is said to be 
anti-parallel When the DNA or RNA strand in a 5‘ to 3‘ 
orientation binds to the complementary PNA strand such 
that the carboxyl end of the PNA is directed toWards the 5‘ 
end of the DNA or RNA and amino end of the PNA is 
directed toWards the 3‘ end of the DNA or RNA. In the 
parallel orientation the carboxyl end and amino end of the 
PNA are just the reverse With respect to the 5‘—3‘ direction 
of the DNA or RNA. 
PNAs bind to both single stranded DNA and double 
stranded DNA. As noted above, in binding to double 
stranded DNA it has been observed that tWo strands of PNA 
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can bind to the DNA. While PNA/DNA duplexes are stable 
in the antiparallel con?guration, it Was previously believed 
that the parallel orientation is preferred for (PNA)2/DNA. 
The binding of tWo single stranded pyrimidine PNAs to a 
double stranded DNA has been shoWn to take place via 
strand displacement, rather than conventional triple helix 
formation as observed With triplexing oligonucleotides. 
When a PNA strand invades double stranded DNA, one 
strand of the DNA is displaced and forms a loop on the side 
of the PNA2/DNA complex area. The other strand of the 
DNA is locked up in the (PNA)2/DNA triplex structure. The 
loop area (alternately referenced as a D loop) being single 
stranded, is susceptible to cleavage by enZymes that can 
cleave single stranded DNA. 
A further advantage of PNAs, compared to 
oligonucleotides, is that the polyamide backbone of PNAs is 
resistant to degradation by enZymes. 
These properties make PNAs useful in several aapplica 
tions. Since PNAs have stronger binding and greater speci 
?city than oligonucleotides, they are used as probes in 
cloning, blotting procedures, and in applications such as 
?uorescence in situ hybridiZation (FISH). Homopyrimidine 
PNAs are used for strand displacement in homopurine 
targets. The restriction sites that overlap With or are adjacent 
to the D-loop are not cleaved by restriction enZymes. Also, 
the local triplex inhibits gene transcription. Thus in binding 
of PNAs to speci?c restriction sites Within a DNA fragment, 
cleavage at those sites can be inhibited. Advantage can be 
taken of this in cloning and subcloning procedures. Labeled 
PNAs are also used to directly map DNA molecules. In 
effecting this, PNA molecules having a ?uorescent label are 
hybridiZed to complementary sequences in duplex DNA 
using strand invasion. 
PNAs have further been used to detect point mutations in 
PCR-based assays (PCR clamping). PCR clamping uses 
PNA to detect point mutations in a PCR-based assay, e.g., 
the distinction betWeen a common Wild type allele and a 
mutant allele, in a segment of DNA under investigation. A 
PNA oligomer complementary to the Wild type sequence is 
synthesiZed. The PCR reaction mixture contains this PNA 
and tWo DNAprimers, one of Which is complementary to the 
mutant sequence. The Wild type PNA oligomer and the DNA 
primer compete for hybridiZation to the target. HybridiZa 
tion of the DNA primer and subsequent ampli?cation Will 
only occur if the target is a mutant allele. With this method, 
one can determine the presence and exact identity of a 
mutant. 
Considerable research is being directed to the application 
of oligonucleotides and oligonucleotide analogs that bind to 
complementary DNA and RNA strands for use as 
diagnostics, research reagents and potential therapeutics. 
For many applications, the oligonucleotides and oligonucle 
otide analogs must be transported across cell membranes or 
taken up by cells to express their activity. 
PCT/EP/01219 describes novel PNAs Which bind to 
complementary DNA and RNA more tightly than the cor 
responding DNA. It is desirable to append groups to these 
PNAs Which Will modulate their activity, modify their 
membrane permiability or increase their cellular uptake 
property. One method for increasing amount of cellular 
uptake property of PNAs is to attach a lipophilic group. 
United States application Ser. No. 117,363, ?led Sep. 3, 
1993, describes several alkylamino functionalities and their 
use in the attachment of such pendant groups to oligonucleo 
sides. 
US application Ser. No. 07/943,516, ?led Sep. 11, 1992, 
and its corresponding published PCT application WO 
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94/06815, describe other novel amine-containing com 
pounds and their incorporation into oligonucleotides for, 
inter alia, the purposes of enhancing cellular uptake, increas 
ing lipophilicity, causing greater cellular retention and 
increasing the distribution of the compound Within the cell. 
US. application Ser. No. 08/116,801, ?led Sep. 3, 1993, 
describes nucleosides and oligonucleosides derivatiZed to 
include a thiolalkyl functionality, through Which pendant 
groups are attached. 
Peptide nucleic acids may contain purine or pyrimidine 
nucleobases. HoWever, previous PNAs having a high purine 
nucleobase content exhibit decreased solubility at physi 
ological pH. PNAs of the present invention overcome this 
problem. 
Despite recent advances, there remains a need for a stable 
compound that enhances or modulates binding to nucleic 
acids, stabiliZes the hybridiZed complexes and increases the 
aqueous solubility. 
SUMMARY OF THE INVENTION 
The present invention provides methods for enhancing the 
solubility, sequence speci?city and binding af?nity of pep 
tide nucleic acids (PNAs), for complementary DNA or 
RNA, by incorporation C1—C8 akylamine side chain into 
PNAs. 
The peptide nucleic acids (PNAs) of the invention gen 
erally comprise ligands linked to a polyamide backbone. 
Representative ligands include the four major naturally 
occurring DNA nucleobases (i.e. thymine, cytosine, adenine 
and guanine), other naturally-occurring nucleobases (e.g. 
inosine, uracil, S-methylcytosine, thiouracil or 2,6 
diaminopurine) or arti?cial bases (e.g. bromothymine, 
aZaadenines or aZaguanines) attached to a polyamide back 
bone through a suitable linker. 
In one aspect, the present invention provides a method for 
enhancing the DNA or RNA sequence speci?city of a 
peptide nucleic acid by incorporating C1—C8 akylamine side 
chain in said peptide nucleic acid having formula (I): 
Wherein: 
each L is independently selected from a group consisting 
of naturally-occurring nucleobases and non-naturally 
occurring nucleobases; 
each R7’ is independently hydrogen or C1—C8 alkylamine, 
provided that at least one R7’ is C1—8 alkylamine; 
Rh is OH, NH2 or NHLysNH2; 
Ri is H, COCH3 or t-butoxycarbonyl; and 
n is an integer from 1 to 30. 
Preferably, at least one R7’ is C3—C6 alkylamine. More 
preferably, at least one R7’ is C4—C5 alkylamine. Even more 
preferably, at least one R7’ is butylamine. Still even more 
preferably, substantially all of the R7’ are butylamine. 
Preferably, the carbon atom to Which substituent R7’ are 
attached is stereochemically enriched. Hereinafter, “stere 
ochemically enriched” means that one stereoisomer is 
present more than the other stereoisomer in a suf?cient 
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amount as to provide a bene?cial effect. Preferably, one 
stereoisomer is present by more than 50%. More preferably, 
one stereoisomer is present by more than 80%. Even more 
preferably, one steroisomer is present by more than 90%. 
Still more preferably, one stereoisomer is present by more 
than 95%. Even more preferably, one stereoisomer is present 
by more than 99%. Still even more preferably, one stereoi 
somer is present in substantially quantitatively. Preferably, 
the stereochemical enrichment is of R con?guration. 
Preferably, the peptide nucleic acid is derived from an 
amino acid. More preferably, the peptide nucleic acid is 
derived from D-lysine. 
The present invention also provides a method for enhanc 
ing the DNA or RNA binding af?nity of a peptide nucleic 
acid by incorporating C1—C8 alkylamine side chain in the 
peptide nucleic acid having formula 
The present invention also provides a method for enhanc 
ing the solubility of a peptide nucleic acid by incorporating 
C1—C8 alkylamine side chain in the peptide nucleic acid 
having formula 
The PNAs of the invention are synthesiZed by adaptation 
of standard peptide synthesis procedures, either in solution 
or on a solid phase. 
In some preferred embodiments, the monomer subunits of 
the invention are amino acids or their activated derivatives, 
protected by standard protecting groups knoWn in the art. 
Preferred monomer subunits according to the present inven 
tion are amino acid compounds having formula (II): 
<11) 
L 
O 
EYNWZ 
R7’ 
Wherein: 
L is a naturally-occurring nucleobase or a non-naturally 
occurring nucleobase, or a protected derivative thereof; 
R7’ is hydrogen or C1—C8 alkylamine; 
E is COOH or an activated or protected derivative thereof; 
and 
Z is NH2 or NHPg, Wherein Pg is an amino-protecting 
group. 
Preferably, R7’ is C3—C6 alkylamine. More preferably, R7’ 
is C4—C5, alkylamine. Still more preferably, R7’ is butyl 
amine. 
The carbon atom to Which substituent R7’ is attached 
(identi?ed by an asterisks) is stereochemically enriched. 
Preferably, the stereochemical enrichment is of R con?gu 
ration. 
Preferably, compound (II) of the present invention is 
derived from an amino acid. More preferably, compound 
(11) of the present invention is derived from D-lysine. 
One aspect of the present invention provides compounds 
of formula (III): 
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L, | 
T 
N CO R 
R8_I|\I/\/ 2 9 
H R1 R5 
Wherein: 
R8 is H or an amine protecting group; 
R9 is H, alkyl having from 1 to about 12 carbon atoms, or 
alkenyl having from 2 to about 12 carbon atoms; 
one of R4 and R5 is H and the other of R4 and R5 is a 
moiety of formula (IV) 
(IV) 
CH2 
\ 
RIO-N 
VN 
Wherein 
R10 is an amine protecting group; 
L‘ is selected from the group consisting of hydrogen, 
hydroXy, (C1—C4)alkanoyl, naturally occurring 
nucleobases, non-naturally occurring nucleobases, aro 
matic moieties, DNA intercalators, nucleobase-binding 
groups, and heterocyclic moieties, reporter ligands, 
Wherein amino groups are, optionally, protected by 
amino protecting groups; 
A is a group of formula (IIa)—(IId): 
(HA) 
R1 R1 | | 
C Y C 
12 12 
(H11) 
R1 R1 X | | || 
C Y C C— 
12 12 
(He) 
R1 R1 R3 X | | | || 
C Y C N—C— 
12 12 
(IId) 
R1 R1 X R3 | | || | 
C Y C C—N— 
12 12 
Where: 
X is O, S, Se, NR3, CH2 or C(CH3)2; 
Y is a single bond, O, S or NR4 Where R4 is as described 
above; 
each r and s is Zero or an integer from 1 to 5; 
each R1 and R2 is independently selected from the group 
consisting of hydrogen, (C1—C4)alkyl Which may be 



















































